provider stringclasses 54 values | name stringclasses 186 values | size stringclasses 120 values | variant stringclasses 110 values | version stringclasses 110 values | sector stringclasses 4 values | openness stringclasses 2 values | region stringclasses 5 values | country stringclasses 13 values | source_id stringclasses 434 values | is_first_party bool 2 classes | category int64 1 7 | year int64 2.02k 2.03k | metadata stringclasses 433 values | score float64 0 3 | is_model_release bool 2 classes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Meta | llama-3.1 | 405B | instruct | Turbo | Industry | open | North America | United States | third-party-leaderboards_43 | false | 2 | 2,025 | {'title': 'Maternal Health Entitlements in Uttar Pradesh, India', 'url': 'https://weval.org/analysis/maternal-health-uttar-pradesh/59aa3bfaf8f1e8fc/2025-08-19T07-26-42-178Z'} | 3 | false |
Anthropic | claude-4.1 | null | opus | null | Industry | closed | North America | United States | third-party-leaderboards_43 | false | 2 | 2,025 | {'title': 'Maternal Health Entitlements in Uttar Pradesh, India', 'url': 'https://weval.org/analysis/maternal-health-uttar-pradesh/59aa3bfaf8f1e8fc/2025-08-19T07-26-42-178Z'} | 3 | false |
Anthropic | claude-3.5 | null | haiku | null | Industry | closed | North America | United States | third-party-leaderboards_43 | false | 2 | 2,025 | {'title': 'Maternal Health Entitlements in Uttar Pradesh, India', 'url': 'https://weval.org/analysis/maternal-health-uttar-pradesh/59aa3bfaf8f1e8fc/2025-08-19T07-26-42-178Z'} | 3 | false |
Mistral | mistral | null | large | 2411 | Industry | open | Europe | France | third-party-leaderboards_43 | false | 2 | 2,025 | {'title': 'Maternal Health Entitlements in Uttar Pradesh, India', 'url': 'https://weval.org/analysis/maternal-health-uttar-pradesh/59aa3bfaf8f1e8fc/2025-08-19T07-26-42-178Z'} | 3 | false |
Anthropic | claude-4 | null | opus | null | Industry | closed | North America | United States | third-party-leaderboards_43 | false | 2 | 2,025 | {'title': 'Maternal Health Entitlements in Uttar Pradesh, India', 'url': 'https://weval.org/analysis/maternal-health-uttar-pradesh/59aa3bfaf8f1e8fc/2025-08-19T07-26-42-178Z'} | 3 | false |
Anthropic | claude-4 | null | sonnet | null | Industry | closed | North America | United States | third-party-leaderboards_43 | false | 2 | 2,025 | {'title': 'Maternal Health Entitlements in Uttar Pradesh, India', 'url': 'https://weval.org/analysis/maternal-health-uttar-pradesh/59aa3bfaf8f1e8fc/2025-08-19T07-26-42-178Z'} | 3 | false |
xAI | grok-4 | null | null | null | Industry | closed | North America | United States | third-party-leaderboards_43 | false | 2 | 2,025 | {'title': 'Maternal Health Entitlements in Uttar Pradesh, India', 'url': 'https://weval.org/analysis/maternal-health-uttar-pradesh/59aa3bfaf8f1e8fc/2025-08-19T07-26-42-178Z'} | 3 | false |
Alibaba | qwen-3 | 30B | instruct | 2507 | Industry | open | East Asia | China | third-party-leaderboards_43 | false | 2 | 2,025 | {'title': 'Maternal Health Entitlements in Uttar Pradesh, India', 'url': 'https://weval.org/analysis/maternal-health-uttar-pradesh/59aa3bfaf8f1e8fc/2025-08-19T07-26-42-178Z'} | 3 | false |
Google | gemini-2.5 | null | flash | null | Industry | closed | North America | United States | third-party-leaderboards_43 | false | 2 | 2,025 | {'title': 'Maternal Health Entitlements in Uttar Pradesh, India', 'url': 'https://weval.org/analysis/maternal-health-uttar-pradesh/59aa3bfaf8f1e8fc/2025-08-19T07-26-42-178Z'} | 3 | false |
Alibaba | qwen-3 | 32B | null | null | Industry | open | East Asia | China | third-party-leaderboards_43 | false | 2 | 2,025 | {'title': 'Maternal Health Entitlements in Uttar Pradesh, India', 'url': 'https://weval.org/analysis/maternal-health-uttar-pradesh/59aa3bfaf8f1e8fc/2025-08-19T07-26-42-178Z'} | 3 | false |
xAI | grok-3 | null | null | null | Industry | closed | North America | United States | third-party-leaderboards_43 | false | 2 | 2,025 | {'title': 'Maternal Health Entitlements in Uttar Pradesh, India', 'url': 'https://weval.org/analysis/maternal-health-uttar-pradesh/59aa3bfaf8f1e8fc/2025-08-19T07-26-42-178Z'} | 3 | false |
Mistral | mistral | null | medium | 3 | Industry | open | Europe | France | third-party-leaderboards_43 | false | 2 | 2,025 | {'title': 'Maternal Health Entitlements in Uttar Pradesh, India', 'url': 'https://weval.org/analysis/maternal-health-uttar-pradesh/59aa3bfaf8f1e8fc/2025-08-19T07-26-42-178Z'} | 3 | false |
Cohere | command-a | null | null | null | Industry | open | North America | Canada | third-party-leaderboards_43 | false | 2 | 2,025 | {'title': 'Maternal Health Entitlements in Uttar Pradesh, India', 'url': 'https://weval.org/analysis/maternal-health-uttar-pradesh/59aa3bfaf8f1e8fc/2025-08-19T07-26-42-178Z'} | 3 | false |
OpenAI | gpt-4 | null | mini | null | Industry | closed | North America | United States | third-party-leaderboards_44 | false | 2 | 2,025 | {'title': 'Japan Clinical Practice Scenarios', 'url': 'https://weval.org/analysis/jp-clinical-scenarios/cdf1542ed86cdbed/2025-08-19T04-13-29-103Z'} | 3 | false |
OpenAI | gpt-4 | null | null | null | Industry | closed | North America | United States | third-party-leaderboards_44 | false | 2 | 2,025 | {'title': 'Japan Clinical Practice Scenarios', 'url': 'https://weval.org/analysis/jp-clinical-scenarios/cdf1542ed86cdbed/2025-08-19T04-13-29-103Z'} | 3 | false |
Anthropic | claude-3.5 | null | haiku | null | Industry | closed | North America | United States | third-party-leaderboards_44 | false | 2 | 2,025 | {'title': 'Japan Clinical Practice Scenarios', 'url': 'https://weval.org/analysis/jp-clinical-scenarios/cdf1542ed86cdbed/2025-08-19T04-13-29-103Z'} | 3 | false |
Cohere | command-a | null | a | null | Industry | open | North America | Canada | third-party-leaderboards_44 | false | 2 | 2,025 | {'title': 'Japan Clinical Practice Scenarios', 'url': 'https://weval.org/analysis/jp-clinical-scenarios/cdf1542ed86cdbed/2025-08-19T04-13-29-103Z'} | 3 | false |
Anthropic | claude-4.1 | null | opus | null | Industry | closed | North America | United States | third-party-leaderboards_44 | false | 2 | 2,025 | {'title': 'Japan Clinical Practice Scenarios', 'url': 'https://weval.org/analysis/jp-clinical-scenarios/cdf1542ed86cdbed/2025-08-19T04-13-29-103Z'} | 3 | false |
Anthropic | claude-4 | null | sonnet | null | Industry | closed | North America | United States | third-party-leaderboards_44 | false | 2 | 2,025 | {'title': 'Japan Clinical Practice Scenarios', 'url': 'https://weval.org/analysis/jp-clinical-scenarios/cdf1542ed86cdbed/2025-08-19T04-13-29-103Z'} | 3 | false |
Z.ai | glm-4.5 | null | null | null | Industry | open | East Asia | China | third-party-leaderboards_44 | false | 2 | 2,025 | {'title': 'Japan Clinical Practice Scenarios', 'url': 'https://weval.org/analysis/jp-clinical-scenarios/cdf1542ed86cdbed/2025-08-19T04-13-29-103Z'} | 3 | false |
Anthropic | claude-3.5 | null | sonnet | null | Industry | closed | North America | United States | third-party-leaderboards_44 | false | 2 | 2,025 | {'title': 'Japan Clinical Practice Scenarios', 'url': 'https://weval.org/analysis/jp-clinical-scenarios/cdf1542ed86cdbed/2025-08-19T04-13-29-103Z'} | 3 | false |
OpenAI | gpt-4.1 | null | nano | null | Industry | closed | North America | United States | third-party-leaderboards_44 | false | 2 | 2,025 | {'title': 'Japan Clinical Practice Scenarios', 'url': 'https://weval.org/analysis/jp-clinical-scenarios/cdf1542ed86cdbed/2025-08-19T04-13-29-103Z'} | 3 | false |
OpenAI | gpt-oss | 120B | null | null | Industry | open | North America | United States | third-party-leaderboards_44 | false | 2 | 2,025 | {'title': 'Japan Clinical Practice Scenarios', 'url': 'https://weval.org/analysis/jp-clinical-scenarios/cdf1542ed86cdbed/2025-08-19T04-13-29-103Z'} | 3 | false |
OpenAI | gpt-oss | 20B | null | null | Industry | open | North America | United States | third-party-leaderboards_44 | false | 2 | 2,025 | {'title': 'Japan Clinical Practice Scenarios', 'url': 'https://weval.org/analysis/jp-clinical-scenarios/cdf1542ed86cdbed/2025-08-19T04-13-29-103Z'} | 3 | false |
Meta | llama-3 | 70B | instruct | null | Industry | open | North America | United States | third-party-leaderboards_44 | false | 2 | 2,025 | {'title': 'Japan Clinical Practice Scenarios', 'url': 'https://weval.org/analysis/jp-clinical-scenarios/cdf1542ed86cdbed/2025-08-19T04-13-29-103Z'} | 3 | false |
xAI | grok-4 | null | null | null | Industry | closed | North America | United States | third-party-leaderboards_44 | false | 2 | 2,025 | {'title': 'Japan Clinical Practice Scenarios', 'url': 'https://weval.org/analysis/jp-clinical-scenarios/cdf1542ed86cdbed/2025-08-19T04-13-29-103Z'} | 3 | false |
Google | gemini-2.5 | null | pro | null | Industry | closed | North America | United States | third-party-leaderboards_44 | false | 2 | 2,025 | {'title': 'Japan Clinical Practice Scenarios', 'url': 'https://weval.org/analysis/jp-clinical-scenarios/cdf1542ed86cdbed/2025-08-19T04-13-29-103Z'} | 3 | false |
Anthropic | claude-3 | null | sonnet | null | Industry | closed | North America | United States | third-party-leaderboards_44 | false | 2 | 2,025 | {'title': 'Japan Clinical Practice Scenarios', 'url': 'https://weval.org/analysis/jp-clinical-scenarios/cdf1542ed86cdbed/2025-08-19T04-13-29-103Z'} | 3 | false |
OpenAI | gpt-4.1 | null | null | null | Industry | closed | North America | United States | third-party-leaderboards_44 | false | 2 | 2,025 | {'title': 'Japan Clinical Practice Scenarios', 'url': 'https://weval.org/analysis/jp-clinical-scenarios/cdf1542ed86cdbed/2025-08-19T04-13-29-103Z'} | 3 | false |
OpenAI | o4 | null | mini | null | Industry | closed | North America | United States | third-party-leaderboards_44 | false | 2 | 2,025 | {'title': 'Japan Clinical Practice Scenarios', 'url': 'https://weval.org/analysis/jp-clinical-scenarios/cdf1542ed86cdbed/2025-08-19T04-13-29-103Z'} | 3 | false |
Mistral | mistral-large | null | null | 2411 | Industry | open | Europe | France | third-party-leaderboards_44 | false | 2 | 2,025 | {'title': 'Japan Clinical Practice Scenarios', 'url': 'https://weval.org/analysis/jp-clinical-scenarios/cdf1542ed86cdbed/2025-08-19T04-13-29-103Z'} | 3 | false |
OpenAI | gpt-5 | null | null | null | Industry | closed | North America | United States | third-party-leaderboards_44 | false | 2 | 2,025 | {'title': 'Japan Clinical Practice Scenarios', 'url': 'https://weval.org/analysis/jp-clinical-scenarios/cdf1542ed86cdbed/2025-08-19T04-13-29-103Z'} | 3 | false |
Alibaba | qwen-3 | 30B | instruct | null | Industry | open | East Asia | China | third-party-leaderboards_44 | false | 2 | 2,025 | {'title': 'Japan Clinical Practice Scenarios', 'url': 'https://weval.org/analysis/jp-clinical-scenarios/cdf1542ed86cdbed/2025-08-19T04-13-29-103Z'} | 3 | false |
DeepSeek | deepseek-v3 | null | chat | null | Industry | open | East Asia | China | third-party-leaderboards_44 | false | 2 | 2,025 | {'title': 'Japan Clinical Practice Scenarios', 'url': 'https://weval.org/analysis/jp-clinical-scenarios/cdf1542ed86cdbed/2025-08-19T04-13-29-103Z'} | 3 | false |
Anthropic | claude-4 | null | opus | null | Industry | closed | North America | United States | third-party-leaderboards_44 | false | 2 | 2,025 | {'title': 'Japan Clinical Practice Scenarios', 'url': 'https://weval.org/analysis/jp-clinical-scenarios/cdf1542ed86cdbed/2025-08-19T04-13-29-103Z'} | 3 | false |
Mistral | mistral-medium | null | null | 3 | Industry | closed | Europe | France | third-party-leaderboards_44 | false | 2 | 2,025 | {'title': 'Japan Clinical Practice Scenarios', 'url': 'https://weval.org/analysis/jp-clinical-scenarios/cdf1542ed86cdbed/2025-08-19T04-13-29-103Z'} | 3 | false |
Meta | llama-4 | null | maverick | null | Industry | open | North America | United States | third-party-leaderboards_44 | false | 2 | 2,025 | {'title': 'Japan Clinical Practice Scenarios', 'url': 'https://weval.org/analysis/jp-clinical-scenarios/cdf1542ed86cdbed/2025-08-19T04-13-29-103Z'} | 3 | false |
Meta | llama-3.1 | 405B | instruct | Turbo | Industry | open | North America | United States | third-party-leaderboards_44 | false | 2 | 2,025 | {'title': 'Japan Clinical Practice Scenarios', 'url': 'https://weval.org/analysis/jp-clinical-scenarios/cdf1542ed86cdbed/2025-08-19T04-13-29-103Z'} | 3 | false |
xAI | grok-3 | null | null | null | Industry | closed | North America | United States | third-party-leaderboards_44 | false | 2 | 2,025 | {'title': 'Japan Clinical Practice Scenarios', 'url': 'https://weval.org/analysis/jp-clinical-scenarios/cdf1542ed86cdbed/2025-08-19T04-13-29-103Z'} | 3 | false |
OpenAI | gpt-4.1 | null | mini | null | Industry | closed | North America | United States | third-party-leaderboards_44 | false | 2 | 2,025 | {'title': 'Japan Clinical Practice Scenarios', 'url': 'https://weval.org/analysis/jp-clinical-scenarios/cdf1542ed86cdbed/2025-08-19T04-13-29-103Z'} | 3 | false |
DeepSeek | deepseek-r1 | null | null | null | Industry | open | East Asia | China | third-party-leaderboards_44 | false | 2 | 2,025 | {'title': 'Japan Clinical Practice Scenarios', 'url': 'https://weval.org/analysis/jp-clinical-scenarios/cdf1542ed86cdbed/2025-08-19T04-13-29-103Z'} | 3 | false |
Alibaba | qwen-3 | 32B | null | null | Industry | open | East Asia | China | third-party-leaderboards_44 | false | 2 | 2,025 | {'title': 'Japan Clinical Practice Scenarios', 'url': 'https://weval.org/analysis/jp-clinical-scenarios/cdf1542ed86cdbed/2025-08-19T04-13-29-103Z'} | 3 | false |
Google | gemini-2.5 | null | flash | null | Industry | closed | North America | United States | third-party-leaderboards_44 | false | 2 | 2,025 | {'title': 'Japan Clinical Practice Scenarios', 'url': 'https://weval.org/analysis/jp-clinical-scenarios/cdf1542ed86cdbed/2025-08-19T04-13-29-103Z'} | 3 | false |
Meta | llama-3 | 70B | instruct | null | Industry | open | North America | United States | third-party-leaderboards_45 | false | 2 | 2,025 | {'title': 'UK Clinical Practice Scenarios (Safety-First, Source-Verified)', 'url': 'https://weval.org/analysis/uk-clinical-scenarios/08278696ca247dbe/2025-08-19T02-24-42-316Z'} | 3 | false |
OpenAI | gpt-4o | null | null | null | Industry | closed | North America | United States | third-party-leaderboards_45 | false | 2 | 2,025 | {'title': 'UK Clinical Practice Scenarios (Safety-First, Source-Verified)', 'url': 'https://weval.org/analysis/uk-clinical-scenarios/08278696ca247dbe/2025-08-19T02-24-42-316Z'} | 3 | false |
Anthropic | claude-4 | null | sonnet | 4 | Industry | closed | North America | United States | third-party-leaderboards_45 | false | 2 | 2,025 | {'title': 'UK Clinical Practice Scenarios (Safety-First, Source-Verified)', 'url': 'https://weval.org/analysis/uk-clinical-scenarios/08278696ca247dbe/2025-08-19T02-24-42-316Z'} | 3 | false |
Mistral | mistral-medium | null | null | 3 | Industry | closed | Europe | France | third-party-leaderboards_45 | false | 2 | 2,025 | {'title': 'UK Clinical Practice Scenarios (Safety-First, Source-Verified)', 'url': 'https://weval.org/analysis/uk-clinical-scenarios/08278696ca247dbe/2025-08-19T02-24-42-316Z'} | 3 | false |
Google | gemini-2.5 | null | pro | null | Industry | closed | North America | United States | third-party-leaderboards_45 | false | 2 | 2,025 | {'title': 'UK Clinical Practice Scenarios (Safety-First, Source-Verified)', 'url': 'https://weval.org/analysis/uk-clinical-scenarios/08278696ca247dbe/2025-08-19T02-24-42-316Z'} | 3 | false |
DeepSeek | deepseek-r1 | null | null | null | Industry | open | East Asia | China | third-party-leaderboards_45 | false | 2 | 2,025 | {'title': 'UK Clinical Practice Scenarios (Safety-First, Source-Verified)', 'url': 'https://weval.org/analysis/uk-clinical-scenarios/08278696ca247dbe/2025-08-19T02-24-42-316Z'} | 3 | false |
OpenAI | gpt-4.1 | null | mini | null | Industry | closed | North America | United States | third-party-leaderboards_45 | false | 2 | 2,025 | {'title': 'UK Clinical Practice Scenarios (Safety-First, Source-Verified)', 'url': 'https://weval.org/analysis/uk-clinical-scenarios/08278696ca247dbe/2025-08-19T02-24-42-316Z'} | 3 | false |
OpenAI | gpt-5 | null | null | null | Industry | closed | North America | United States | third-party-leaderboards_45 | false | 2 | 2,025 | {'title': 'UK Clinical Practice Scenarios (Safety-First, Source-Verified)', 'url': 'https://weval.org/analysis/uk-clinical-scenarios/08278696ca247dbe/2025-08-19T02-24-42-316Z'} | 3 | false |
OpenAI | o4 | null | mini | null | Industry | closed | North America | United States | third-party-leaderboards_45 | false | 2 | 2,025 | {'title': 'UK Clinical Practice Scenarios (Safety-First, Source-Verified)', 'url': 'https://weval.org/analysis/uk-clinical-scenarios/08278696ca247dbe/2025-08-19T02-24-42-316Z'} | 3 | false |
OpenAI | gpt-oss | 120B | null | null | Industry | open | North America | United States | third-party-leaderboards_45 | false | 2 | 2,025 | {'title': 'UK Clinical Practice Scenarios (Safety-First, Source-Verified)', 'url': 'https://weval.org/analysis/uk-clinical-scenarios/08278696ca247dbe/2025-08-19T02-24-42-316Z'} | 3 | false |
OpenAI | gpt-oss | 20B | null | null | Industry | open | North America | United States | third-party-leaderboards_45 | false | 2 | 2,025 | {'title': 'UK Clinical Practice Scenarios (Safety-First, Source-Verified)', 'url': 'https://weval.org/analysis/uk-clinical-scenarios/08278696ca247dbe/2025-08-19T02-24-42-316Z'} | 3 | false |
OpenAI | gpt-4.1 | null | null | null | Industry | closed | North America | United States | third-party-leaderboards_45 | false | 2 | 2,025 | {'title': 'UK Clinical Practice Scenarios (Safety-First, Source-Verified)', 'url': 'https://weval.org/analysis/uk-clinical-scenarios/08278696ca247dbe/2025-08-19T02-24-42-316Z'} | 3 | false |
Cohere | command-a | null | null | null | Industry | open | North America | Canada | third-party-leaderboards_45 | false | 2 | 2,025 | {'title': 'UK Clinical Practice Scenarios (Safety-First, Source-Verified)', 'url': 'https://weval.org/analysis/uk-clinical-scenarios/08278696ca247dbe/2025-08-19T02-24-42-316Z'} | 3 | false |
Anthropic | claude-1 | null | opus | 4.1 | Industry | closed | North America | United States | third-party-leaderboards_45 | false | 2 | 2,025 | {'title': 'UK Clinical Practice Scenarios (Safety-First, Source-Verified)', 'url': 'https://weval.org/analysis/uk-clinical-scenarios/08278696ca247dbe/2025-08-19T02-24-42-316Z'} | 3 | false |
Alibaba | qwen-3 | 32B | null | null | Industry | open | East Asia | China | third-party-leaderboards_45 | false | 2 | 2,025 | {'title': 'UK Clinical Practice Scenarios (Safety-First, Source-Verified)', 'url': 'https://weval.org/analysis/uk-clinical-scenarios/08278696ca247dbe/2025-08-19T02-24-42-316Z'} | 3 | false |
Z.ai | glm-4.5 | null | null | null | Industry | open | East Asia | China | third-party-leaderboards_45 | false | 2 | 2,025 | {'title': 'UK Clinical Practice Scenarios (Safety-First, Source-Verified)', 'url': 'https://weval.org/analysis/uk-clinical-scenarios/08278696ca247dbe/2025-08-19T02-24-42-316Z'} | 3 | false |
OpenAI | gpt-4o | null | mini | null | Industry | closed | North America | United States | third-party-leaderboards_45 | false | 2 | 2,025 | {'title': 'UK Clinical Practice Scenarios (Safety-First, Source-Verified)', 'url': 'https://weval.org/analysis/uk-clinical-scenarios/08278696ca247dbe/2025-08-19T02-24-42-316Z'} | 3 | false |
Anthropic | claude-3.7 | null | sonnet | null | Industry | closed | North America | United States | third-party-leaderboards_45 | false | 2 | 2,025 | {'title': 'UK Clinical Practice Scenarios (Safety-First, Source-Verified)', 'url': 'https://weval.org/analysis/uk-clinical-scenarios/08278696ca247dbe/2025-08-19T02-24-42-316Z'} | 3 | false |
Mistral | mistral-large | null | null | 2411 | Industry | open | Europe | France | third-party-leaderboards_45 | false | 2 | 2,025 | {'title': 'UK Clinical Practice Scenarios (Safety-First, Source-Verified)', 'url': 'https://weval.org/analysis/uk-clinical-scenarios/08278696ca247dbe/2025-08-19T02-24-42-316Z'} | 3 | false |
Anthropic | claude-3.5 | null | haiku | null | Industry | closed | North America | United States | third-party-leaderboards_45 | false | 2 | 2,025 | {'title': 'UK Clinical Practice Scenarios (Safety-First, Source-Verified)', 'url': 'https://weval.org/analysis/uk-clinical-scenarios/08278696ca247dbe/2025-08-19T02-24-42-316Z'} | 3 | false |
Anthropic | claude-3.5 | null | sonnet | null | Industry | closed | North America | United States | third-party-leaderboards_45 | false | 2 | 2,025 | {'title': 'UK Clinical Practice Scenarios (Safety-First, Source-Verified)', 'url': 'https://weval.org/analysis/uk-clinical-scenarios/08278696ca247dbe/2025-08-19T02-24-42-316Z'} | 3 | false |
Anthropic | claude-4 | null | opus | null | Industry | closed | North America | United States | third-party-leaderboards_45 | false | 2 | 2,025 | {'title': 'UK Clinical Practice Scenarios (Safety-First, Source-Verified)', 'url': 'https://weval.org/analysis/uk-clinical-scenarios/08278696ca247dbe/2025-08-19T02-24-42-316Z'} | 3 | false |
Meta | llama-3.1 | 405B | instruct | Turbo | Industry | open | North America | United States | third-party-leaderboards_45 | false | 2 | 2,025 | {'title': 'UK Clinical Practice Scenarios (Safety-First, Source-Verified)', 'url': 'https://weval.org/analysis/uk-clinical-scenarios/08278696ca247dbe/2025-08-19T02-24-42-316Z'} | 3 | false |
OpenAI | gpt-4.1 | null | mini | null | Industry | closed | North America | United States | third-party-leaderboards_45 | false | 2 | 2,025 | {'title': 'UK Clinical Practice Scenarios (Safety-First, Source-Verified)', 'url': 'https://weval.org/analysis/uk-clinical-scenarios/08278696ca247dbe/2025-08-19T02-24-42-316Z'} | 3 | false |
xAI | grok-4 | null | null | null | Industry | closed | North America | United States | third-party-leaderboards_45 | false | 2 | 2,025 | {'title': 'UK Clinical Practice Scenarios (Safety-First, Source-Verified)', 'url': 'https://weval.org/analysis/uk-clinical-scenarios/08278696ca247dbe/2025-08-19T02-24-42-316Z'} | 3 | false |
DeepSeek | deepseek | null | chat | V3 | Industry | open | East Asia | China | third-party-leaderboards_45 | false | 2 | 2,025 | {'title': 'UK Clinical Practice Scenarios (Safety-First, Source-Verified)', 'url': 'https://weval.org/analysis/uk-clinical-scenarios/08278696ca247dbe/2025-08-19T02-24-42-316Z'} | 3 | false |
Google | gemini-2.5 | null | flash | null | Industry | closed | North America | United States | third-party-leaderboards_45 | false | 2 | 2,025 | {'title': 'UK Clinical Practice Scenarios (Safety-First, Source-Verified)', 'url': 'https://weval.org/analysis/uk-clinical-scenarios/08278696ca247dbe/2025-08-19T02-24-42-316Z'} | 3 | false |
Meta | llama-4 | null | maverick | null | Industry | open | North America | United States | third-party-leaderboards_45 | false | 2 | 2,025 | {'title': 'UK Clinical Practice Scenarios (Safety-First, Source-Verified)', 'url': 'https://weval.org/analysis/uk-clinical-scenarios/08278696ca247dbe/2025-08-19T02-24-42-316Z'} | 3 | false |
Alibaba | qwen-3 | 30B | instruct | 2507 | Industry | open | East Asia | China | third-party-leaderboards_45 | false | 2 | 2,025 | {'title': 'UK Clinical Practice Scenarios (Safety-First, Source-Verified)', 'url': 'https://weval.org/analysis/uk-clinical-scenarios/08278696ca247dbe/2025-08-19T02-24-42-316Z'} | 3 | false |
xAI | grok-3 | null | null | null | Industry | closed | North America | United States | third-party-leaderboards_45 | false | 2 | 2,025 | {'title': 'UK Clinical Practice Scenarios (Safety-First, Source-Verified)', 'url': 'https://weval.org/analysis/uk-clinical-scenarios/08278696ca247dbe/2025-08-19T02-24-42-316Z'} | 3 | false |
Anthropic | claude-3.5 | null | sonnet | 3.5 | Industry | closed | North America | United States | third-party-leaderboards_46 | false | 1 | 2,025 | {'title': 'BBQ Scenario Variants: Religion, Age, Gender (MCQ + Open)', 'url': 'https://weval.org/analysis/bbq-scenario-variants/3ddce4cc12f1476b/2025-08-18T10-59-53-712Z'} | 3 | false |
Anthropic | claude-4.1 | null | opus | null | Industry | closed | North America | United States | third-party-leaderboards_46 | false | 1 | 2,025 | {'title': 'BBQ Scenario Variants: Religion, Age, Gender (MCQ + Open)', 'url': 'https://weval.org/analysis/bbq-scenario-variants/3ddce4cc12f1476b/2025-08-18T10-59-53-712Z'} | 3 | false |
OpenAI | gpt-oss | 20B | null | null | Industry | open | North America | United States | third-party-leaderboards_46 | false | 1 | 2,025 | {'title': 'BBQ Scenario Variants: Religion, Age, Gender (MCQ + Open)', 'url': 'https://weval.org/analysis/bbq-scenario-variants/3ddce4cc12f1476b/2025-08-18T10-59-53-712Z'} | 3 | false |
Cohere | command-a | null | null | null | Industry | open | North America | Canada | third-party-leaderboards_46 | false | 1 | 2,025 | {'title': 'BBQ Scenario Variants: Religion, Age, Gender (MCQ + Open)', 'url': 'https://weval.org/analysis/bbq-scenario-variants/3ddce4cc12f1476b/2025-08-18T10-59-53-712Z'} | 3 | false |
Anthropic | claude-3.7 | null | sonnet | null | Industry | closed | North America | United States | third-party-leaderboards_46 | false | 1 | 2,025 | {'title': 'BBQ Scenario Variants: Religion, Age, Gender (MCQ + Open)', 'url': 'https://weval.org/analysis/bbq-scenario-variants/3ddce4cc12f1476b/2025-08-18T10-59-53-712Z'} | 3 | false |
OpenAI | gpt-oss | 120B | null | null | Industry | open | North America | United States | third-party-leaderboards_46 | false | 1 | 2,025 | {'title': 'BBQ Scenario Variants: Religion, Age, Gender (MCQ + Open)', 'url': 'https://weval.org/analysis/bbq-scenario-variants/3ddce4cc12f1476b/2025-08-18T10-59-53-712Z'} | 3 | false |
Meta | llama-3.1 | 405B | instruct | turbo | Industry | open | North America | United States | third-party-leaderboards_46 | false | 1 | 2,025 | {'title': 'BBQ Scenario Variants: Religion, Age, Gender (MCQ + Open)', 'url': 'https://weval.org/analysis/bbq-scenario-variants/3ddce4cc12f1476b/2025-08-18T10-59-53-712Z'} | 3 | false |
Meta | llama-3 | 70B | instruct | null | Industry | open | North America | United States | third-party-leaderboards_46 | false | 1 | 2,025 | {'title': 'BBQ Scenario Variants: Religion, Age, Gender (MCQ + Open)', 'url': 'https://weval.org/analysis/bbq-scenario-variants/3ddce4cc12f1476b/2025-08-18T10-59-53-712Z'} | 3 | false |
xAI | grok-4 | null | null | null | Industry | closed | North America | United States | third-party-leaderboards_46 | false | 1 | 2,025 | {'title': 'BBQ Scenario Variants: Religion, Age, Gender (MCQ + Open)', 'url': 'https://weval.org/analysis/bbq-scenario-variants/3ddce4cc12f1476b/2025-08-18T10-59-53-712Z'} | 3 | false |
OpenAI | gpt-4.1 | null | null | null | Industry | closed | North America | United States | third-party-leaderboards_46 | false | 1 | 2,025 | {'title': 'BBQ Scenario Variants: Religion, Age, Gender (MCQ + Open)', 'url': 'https://weval.org/analysis/bbq-scenario-variants/3ddce4cc12f1476b/2025-08-18T10-59-53-712Z'} | 3 | false |
Anthropic | claude-3.5 | null | haiku | null | Industry | closed | North America | United States | third-party-leaderboards_46 | false | 1 | 2,025 | {'title': 'BBQ Scenario Variants: Religion, Age, Gender (MCQ + Open)', 'url': 'https://weval.org/analysis/bbq-scenario-variants/3ddce4cc12f1476b/2025-08-18T10-59-53-712Z'} | 3 | false |
OpenAI | o4 | null | mini | null | Industry | closed | North America | United States | third-party-leaderboards_46 | false | 1 | 2,025 | {'title': 'BBQ Scenario Variants: Religion, Age, Gender (MCQ + Open)', 'url': 'https://weval.org/analysis/bbq-scenario-variants/3ddce4cc12f1476b/2025-08-18T10-59-53-712Z'} | 3 | false |
xAI | grok-3 | null | null | null | Industry | closed | North America | United States | third-party-leaderboards_46 | false | 1 | 2,025 | {'title': 'BBQ Scenario Variants: Religion, Age, Gender (MCQ + Open)', 'url': 'https://weval.org/analysis/bbq-scenario-variants/3ddce4cc12f1476b/2025-08-18T10-59-53-712Z'} | 3 | false |
Z.ai | glm-4.5 | null | null | null | Industry | open | East Asia | China | third-party-leaderboards_46 | false | 1 | 2,025 | {'title': 'BBQ Scenario Variants: Religion, Age, Gender (MCQ + Open)', 'url': 'https://weval.org/analysis/bbq-scenario-variants/3ddce4cc12f1476b/2025-08-18T10-59-53-712Z'} | 3 | false |
Alibaba | qwen-3 | 30B | instruct | null | Industry | open | East Asia | China | third-party-leaderboards_46 | false | 1 | 2,025 | {'title': 'BBQ Scenario Variants: Religion, Age, Gender (MCQ + Open)', 'url': 'https://weval.org/analysis/bbq-scenario-variants/3ddce4cc12f1476b/2025-08-18T10-59-53-712Z'} | 3 | false |
Mistral | mistral-medium | null | null | null | Industry | closed | Europe | France | third-party-leaderboards_46 | false | 1 | 2,025 | {'title': 'BBQ Scenario Variants: Religion, Age, Gender (MCQ + Open)', 'url': 'https://weval.org/analysis/bbq-scenario-variants/3ddce4cc12f1476b/2025-08-18T10-59-53-712Z'} | 3 | false |
Alibaba | qwen-3 | 32B | null | null | Industry | open | East Asia | China | third-party-leaderboards_46 | false | 1 | 2,025 | {'title': 'BBQ Scenario Variants: Religion, Age, Gender (MCQ + Open)', 'url': 'https://weval.org/analysis/bbq-scenario-variants/3ddce4cc12f1476b/2025-08-18T10-59-53-712Z'} | 3 | false |
Mistral | mistral-large | null | null | null | Industry | open | Europe | France | third-party-leaderboards_46 | false | 1 | 2,025 | {'title': 'BBQ Scenario Variants: Religion, Age, Gender (MCQ + Open)', 'url': 'https://weval.org/analysis/bbq-scenario-variants/3ddce4cc12f1476b/2025-08-18T10-59-53-712Z'} | 3 | false |
DeepSeek | deepseek-v3 | null | chat | null | Industry | open | East Asia | China | third-party-leaderboards_46 | false | 1 | 2,025 | {'title': 'BBQ Scenario Variants: Religion, Age, Gender (MCQ + Open)', 'url': 'https://weval.org/analysis/bbq-scenario-variants/3ddce4cc12f1476b/2025-08-18T10-59-53-712Z'} | 3 | false |
OpenAI | gpt-4.1 | null | mini | null | Industry | closed | North America | United States | third-party-leaderboards_46 | false | 1 | 2,025 | {'title': 'BBQ Scenario Variants: Religion, Age, Gender (MCQ + Open)', 'url': 'https://weval.org/analysis/bbq-scenario-variants/3ddce4cc12f1476b/2025-08-18T10-59-53-712Z'} | 3 | false |
OpenAI | gpt-4.1 | null | null | null | Industry | closed | North America | United States | third-party-leaderboards_46 | false | 1 | 2,025 | {'title': 'BBQ Scenario Variants: Religion, Age, Gender (MCQ + Open)', 'url': 'https://weval.org/analysis/bbq-scenario-variants/3ddce4cc12f1476b/2025-08-18T10-59-53-712Z'} | 3 | false |
OpenAI | gpt-4 | null | mini | null | Industry | closed | North America | United States | third-party-leaderboards_46 | false | 1 | 2,025 | {'title': 'BBQ Scenario Variants: Religion, Age, Gender (MCQ + Open)', 'url': 'https://weval.org/analysis/bbq-scenario-variants/3ddce4cc12f1476b/2025-08-18T10-59-53-712Z'} | 3 | false |
OpenAI | gpt-5 | null | null | null | Industry | closed | North America | United States | third-party-leaderboards_46 | false | 1 | 2,025 | {'title': 'BBQ Scenario Variants: Religion, Age, Gender (MCQ + Open)', 'url': 'https://weval.org/analysis/bbq-scenario-variants/3ddce4cc12f1476b/2025-08-18T10-59-53-712Z'} | 3 | false |
OpenAI | gpt-4 | null | null | null | Industry | closed | North America | United States | third-party-leaderboards_46 | false | 1 | 2,025 | {'title': 'BBQ Scenario Variants: Religion, Age, Gender (MCQ + Open)', 'url': 'https://weval.org/analysis/bbq-scenario-variants/3ddce4cc12f1476b/2025-08-18T10-59-53-712Z'} | 3 | false |
Anthropic | claude-4 | null | opus | null | Industry | closed | North America | United States | third-party-leaderboards_46 | false | 1 | 2,025 | {'title': 'BBQ Scenario Variants: Religion, Age, Gender (MCQ + Open)', 'url': 'https://weval.org/analysis/bbq-scenario-variants/3ddce4cc12f1476b/2025-08-18T10-59-53-712Z'} | 3 | false |
Google | gemini-2.5 | null | flash | null | Industry | closed | North America | United States | third-party-leaderboards_46 | false | 1 | 2,025 | {'title': 'BBQ Scenario Variants: Religion, Age, Gender (MCQ + Open)', 'url': 'https://weval.org/analysis/bbq-scenario-variants/3ddce4cc12f1476b/2025-08-18T10-59-53-712Z'} | 3 | false |
Meta | llama-4 | null | null | null | Industry | open | North America | United States | third-party-leaderboards_46 | false | 1 | 2,025 | {'title': 'BBQ Scenario Variants: Religion, Age, Gender (MCQ + Open)', 'url': 'https://weval.org/analysis/bbq-scenario-variants/3ddce4cc12f1476b/2025-08-18T10-59-53-712Z'} | 3 | false |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.